NYSE:AZN

AstraZeneca Stock Forecast, Price & News

$54.80

-0.31 (-0.56 %)

(As of 09/30/2020 12:00 AM ET)

Add

Compare

Today's Range

$54.61

Now: $54.80▼

$55.45

50-Day Range

$53.07

MA: $55.30▼

$57.01

52-Week Range

$36.15

Now: $54.80▼

$64.94

Volume2.99 million shs

Average Volume5.23 million shs

Market Capitalization$143.82 billion

P/E Ratio66.02

Dividend Yield1.60%

Beta0.5

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Beat the Market (BTM) Rank^™

2.2 Analyst's Opinion

Consensus Rating
AstraZeneca has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 7 buy ratings, 2 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $61.67, AstraZeneca has a forecasted upside of 12.5% from its current price of $54.80.
Amount of Analyst Coverage
AstraZeneca has only been the subject of 3 research reports in the past 90 days.

1.9 Community Rank

Outperform Votes
AstraZeneca has received 751 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AstraZeneca has received 1,237 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AstraZeneca has received 62.22% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote “Outperform” if you believe AZN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
AstraZeneca pays a meaningful dividend of 1.60%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of AstraZeneca is 50.29%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 34.38% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 16.30% of the stock of AstraZeneca is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for AstraZeneca are expected to grow by 26.11% in the coming year, from $2.03 to $2.56 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is 66.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.66.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is 66.02, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.31.
Price to Earnings Growth Ratio
AstraZeneca has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AstraZeneca has a P/B Ratio of 9.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.58 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:AZN

Previous Symbol

CUSIPN/A

CIK901832

Webwww.astrazeneca.com

Phone44-20-3749-5000

Debt

Debt-to-Equity Ratio1.14

Current Ratio0.82

Quick Ratio0.63

Price-To-Earnings

Trailing P/E Ratio66.02

Forward P/E Ratio27.00

P/E Growth1.63

Sales & Book Value

Annual Sales$24.38 billion

Price / Sales5.90

Cash Flow$3.13 per share

Price / Cash Flow17.52

Book Value$5.56 per share

Price / Book9.86

Profitability

EPS (Most Recent Fiscal Year)$1.75

Net Income$1.34 billion

Net Margins8.36%

Return on Equity37.72%

Return on Assets8.60%

Miscellaneous

Employees70,600

Outstanding Shares2,624,374,000

Market Cap$143.82 billion

Next Earnings Date10/22/2020 (Estimated)

OptionableOptionable

$54.80

-0.31 (-0.56 %)

(As of 09/30/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

AstraZeneca (NYSE:AZN) Frequently Asked Questions

How has AstraZeneca's stock been impacted by COVID-19?

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AZN shares have increased by 22.9% and is now trading at $54.80.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of AstraZeneca?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for AstraZeneca.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) released its earnings results on Thursday, July, 30th. The company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.04. The firm had revenue of $6.28 billion for the quarter, compared to analyst estimates of $6.27 billion. AstraZeneca had a return on equity of 37.72% and a net margin of 8.36%. AstraZeneca's quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.73 earnings per share.
View AstraZeneca's earnings history.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semi-annual dividend on Friday, July 31st. Stockholders of record on Friday, August 14th will be paid a dividend of $0.45 per share on Monday, September 14th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 13th.
View AstraZeneca's dividend history.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca's stock split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

What price target have analysts set for AZN?

11 analysts have issued 12-month price objectives for AstraZeneca's shares. Their forecasts range from $60.00 to $65.00. On average, they expect AstraZeneca's stock price to reach $61.67 in the next year. This suggests a possible upside of 12.5% from the stock's current price.
View analysts' price targets for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

News articles about AZN stock have trended somewhat negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. AstraZeneca earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about AstraZeneca.

Are investors shorting AstraZeneca?

AstraZeneca saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 4,130,000 shares, a decrease of 37.2% from the August 15th total of 6,580,000 shares. Based on an average daily trading volume, of 6,690,000 shares, the short-interest ratio is presently 0.6 days.
View AstraZeneca's Short Interest.

Who are some of AstraZeneca's key competitors?

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Zoetis (ZTS) and Celgene (CELG).
View all competitors.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), Gilead Sciences (GILD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Moderna (MRNA), Tesla (TSLA), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:

Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
Thomas Kudsk Larsen, Head of Investor Relations
Mr. Jefrey Pott, Gen. Counsel

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $54.80.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $143.82 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 70,600 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings